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Comprehensive rare variant analysis using whole genome sequencing to 
determine the molecular pathology of inherited retinal disease  
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Abstract 
Inherited retinal disease is a common cause of visual impairment, and represents a 
highly heterogeneous group of conditions. Here, we present findings from a cohort of 
722 individuals with inherited retinal disease, who have had whole genome 
sequencing (n=605), whole exome sequencing (n=72), or both (n=45) performed, as 
part of the NIHR-BioResource Rare Diseases research study. We identified 
pathogenic variants (single nucleotide variants, indels, or structural variants) for 
404/722 (56%) individuals. Whole genome sequencing gives unprecedented power 
to detect three categories of pathogenic variants in particular: structural variants, 
variants in GC-rich regions, which have significantly improved coverage compared to 
whole exome sequencing, and variants in non-coding regulatory regions. In addition 
to previously reported pathogenic regulatory variants, we have identified a previously 
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unreported pathogenic intronic variant in the CHM in two males with choroideremia. 
We have also identified 19 genes not previously known to be associated with 
inherited retinal disease, which harbour biallelic predicted protein-truncating variants 
in unsolved cases. Whole genome sequencing is an increasingly important 
comprehensive method with which to investigate the genetic causes of inherited 
retinal disease. 
 
 
 
Introduction 
Inherited retinal disease (IRD) describes a phenotypically heterogeneous group of 
conditions consequent upon dysfunction and/or degeneration of the neural retina or 
retinal pigment epithelium, resulting in visual impairment. IRD is the most common 
cause of severe visual impairment among working age individuals in the UK.1 
Determining the genetic cause of IRD in affected individuals allows accurate 
assessment of risk of the disease to other family members, provides useful 
prognostic information for affected individuals, and can provide much needed insight 
and understanding of the disease for those affected. Furthermore, genetic 
stratification of affected individuals is increasingly being used to direct specific 
treatment options, including clinical trials of medicines and restoration of protein 
function through gene therapy trials.2  
Whole exome sequencing (WES) of large cohorts of individuals has transformed 
research into rare Mendelian diseases in recent years by facilitating discovery of 
pathogenic variants, newly described disease-associated genes, and other insights 
into the genetic architecture of rare diseases.3–5 Whole genome sequencing (WGS) 
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has thus far typically been employed on a smaller scale, and has demonstrated 
advantages over other methods.6,7 Large-scale projects such as the Genomics 
England 100,000 Genome Project are also beginning to use WGS to investigate rare 
diseases.8 
IRD represents a particularly good clinical phenotype to provide comprehensive 
investigation by high-throughput sequencing technologies because it exhibits a high 
degree of phenotypic, genetic and allelic heterogeneity, with over 250 genes and loci 
associated with autosomal dominant, autosomal recessive, X-linked and 
mitochondrial inheritance (RetNet), and it is often difficult to predict the disease-
associated gene from an individual’s phenotype alone.9 IRD is therefore among the 
many rare diseases that are increasingly being investigated through high-throughput 
sequencing.10–13 These technologies are also transforming clinical practice by being 
incorporated into diagnostic services.14,15 Most of these studies have used targeted 
pull-down of a predetermined panel of known genes, which are limited not only in 
that they only cover certain genes, but also because they cannot reliably detect 
structural variants (SVs). WES, on the other hand, is not limited to known disease-
associated genes, but coverage is generally variable across the exome, negatively 
affecting variant detection compared to targeted gene panel testing.16 PCR-free 
WGS should overcome the disadvantages of WES and targeted gene panels, 
although the remaining challenge will be in handling the large amount of data 
generated, and variant interpretation. Indeed, a recent study compared WGS to 
targeted gene panels and found that WGS improves the pathogenic variant detection 
rate by facilitating detection of SVs and variants in regulatory regions.17  
The aims of the current study were threefold. First, to identify pathogenic variants in 
a large cohort of individuals with IRD, including intractable cases in which previous 
investigations had not yielded a diagnosis. Second, to explore advantages and 
disadvantages of WGS as a tool with which to investigate IRD. Third, to identify 
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candidate IRD-associated genes, and provide new insights into phenotypes and the 
genetic architecture of IRD. Here we present a cohort of 722 individuals with IRD, 
who have had high-throughput sequencing as part of the NIHR-BioResource Rare 
Diseases research study.  
 
Methods 
Cohort 
722 individuals with IRD were recruited to the NIHR BioResource Rare Diseases 
research study. All participants provided written informed consent and the study was 
approved by the East of England Cambridge South national institutional review board 
(13/EE/0325). Most of the individuals (n= 657) were recruited at the Inherited Eye 
Disease clinics, Moorfields Eye Hospital NHS Foundation Trust (London, UK). The 
remainder were recruited at Cambridge University Hospitals NHS Foundation Trust 
(Cambridge, UK), Great Ormond Street Hospital For Children NHS Foundation Trust 
(London, UK), Guy's And St Thomas' NHS Foundation Trust (London, UK), London 
North West Healthcare NHS Trust (London, UK), and University College London 
Hospitals NHS Foundation Trust (London, UK). 
Most individuals had undergone some previous genetic testing using routine 
diagnostic approaches (direct Sanger sequencing of highly suggestive genes based 
on clinical characteristics, direct sequencing of candidate genes in gene discovery 
projects and arrayed primer extension (APEX, Asper Biotech Ltd, Tartu, Estonia) 
assays for retinitis pigmentosa [MIM: 268000] and Leber congenital amaurosis (LCA 
[MIM: 204000]). Individuals with no likely pathogenic variant detected by these 
methods were recruited to the study although systematic documentation of pre-
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screening of all cases was not available. 152 individuals of the cohort had no pre-
screening performed. 
High throughput sequencing 
WES and WGS were performed as previously described.18,19 Genome build GRCh37 
was used for mapping and variant calling. SVs were identified in the individuals who 
had WGS using two independent algorithms: Isaac Copy Number Variant Caller 
(Canvas, Illumina), which identifies copy number gains and deletions based on read 
depth, and Isaac Structural Variant Caller (Manta, Illumina), which identifies 
translocations, deletions, tandem duplications, insertions, and inversions based on 
both paired read fragment spanning and split read evidence.20  
To identify the likely ethnicity of each individual, a principal component analysis was 
performed on WGS data from individuals of various ethnicities in the 1000 genomes 
project with 20,000 single nucleotide variants (SNVs) using PLINK.21 The location of 
the centre of the cluster of each ethnicity was then calculated, and a likely ethnicity 
assigned to each of the WGS samples based on the closest cluster. 
 
Variant interpretation 
To facilitate variant interpretation, a list of reported IRD-associated genes was 
assembled, including genes associated with syndromic forms of IRD or albinism, 
from various sources including RetNet and literature searches. This list was manually 
curated according to published evidence of pathogenicity to compile a shortlist of 224 
high-confidence IRD-associated genes (table S1).22 
To identify pathogenic variants, a two-step variant filtering protocol was designed, 
utilising automated filtering followed by manual review. For SNVs and indels, 
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automated filtering identified variants that fulfil the following criteria: passes standard 
Illumina quality filters in >80% of the whole NIHR BioResource Rare Diseases cohort 
(n = 6688); predicted to be a high impact, medium impact, or splice region variant, or 
present in the HGMD Pro database;23 and has minor allele frequency (MAF) <0.01 in 
control datasets including the NIHR BioResource Rare Diseases cohort and the 
Exome Aggregation Consortium (ExAC) database.24 If a variant is present in the 
HGMD Pro database a higher MAF threshold of 0.1 was used. Finally, we identified 
just those variants that affect an IRD-associated gene. In one individual (G002628) 
with hypomagnesemia and retinitis pigmentosa, we interrogated known 
hypomagnesemia-associated genes in addition to IRD-associated genes. For SVs in 
the WGS data, automated filtering identified variants that fulfil the following criteria: 
passes standard Illumina quality filters; overlaps at least one exon; does not overlap 
known benign SVs in healthy cohorts;25 has MAF <0.01 in the NIHR BioResource 
Rare Diseases cohort, and affects an IRD-associated gene.  
Manual review of all the variants that passed the automated filtering was then 
performed. The variant is considered to be pathogenic if it fulfils the following criteria. 
First, the genotype and frequency of the variant is consistent with the expected mode 
of inheritance of the individual’s family (if known), and with the expected mode of 
inheritance of the gene. Second, the phenotype of the individual is consistent with 
the phenotype known to be associated with the gene. Third, the variant is predicted 
to result in truncation of the protein, or it is predicted to be damaging to the protein 
using scores such as CADD,26 or it has previously been reported as pathogenic in 
HGMD Pro. Fourth, the variant appears to be of good quality upon examination of the 
sequencing reads with Integrative Genomics Viewer (IGV).27 Fifth, the variant affects 
the Ensembl canonical transcript or a known retinal transcript. 
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Variant confirmations 
A subset of the pathogenic SNVs and indels was confirmed by Sanger sequencing 
using standard protocols. For SVs, Sanger sequencing was performed across the 
predicted breakpoints to generate a unique junction fragment sequence. Genotyping 
using HumanCoreExome-24 v1.0 BeadChip (Illumina) was also performed, followed 
by SV identification using GenomeStudio and cnvPartition software (Illumina). 
Sequences of all primers are available on request. 
 
Comparing coverage of WGS and WES datasets 
Protein-coding regions of the Ensembl canonical transcript of each autosomal IRD-
associated gene were split into 50bp bins. The mean GC% of each bin was 
calculated using data available from the UCSC genome browser. The mean 
coverage of each bin was calculated across a sample of 100 individuals with IRD in 
the NIHR BioResource Rare Diseases cohort (WGS data), and also in the ExAC 
cohort, for which per-base coverage has been previously published on 10% of the 
cohort.24 We used the ExAC WES dataset for the comparison of the coverage of 
IRD-associated genes, rather than the WES data generated as part of this study, 
because ExAC was used as a frequency control set in this study, and because it is 
based on > 60,000 individuals. 
Coverage data are presented as relative to the mean coverage of all bins (34.4X in 
the WGS dataset, and 65.6X in ExAC). Coverage for each observed range of GC 
content (20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, and 80-90%) was 
compared using one-tailed Mann-Whitney U tests. P values were corrected for 
testing of 7 observed ranges of GC content. 
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Variant analysis in the CHM  
Two individuals with a clinical diagnosis of choroideremia [MIM: 303100] in whom no 
pathogenic coding variant was found, underwent intronic variant analysis of CHM 
([MIM: 300390]; ENST00000357749.2, GRCh37/hg19 chrX:85,116,185-85,302,566). 
Intronic variants in CHM that passed standard quality filters and had a MAF ≤0.01 in 
the UK10K WGS cohort and the NIHR BioResource Rare Diseases cohort were 
prioritised for analysis. Splice site prediction of the reference and alternate 
sequences were compared using Human Splice Finder V3.0 (HSF) and 
NNSPLICE0.9.28,29 We identified a candidate variant that was confirmed by direct 
Sanger sequencing of genomic DNA from affected members of both families and an 
obligate carrier. Reverse transcription PCR (RT-PCR) spanning CHM exons 4-5 was 
carried out on total RNA isolated from peripheral blood mononuclear cells.  
 
Identification of genes containing likely biallelic predicted protein-truncating 
variants in unsolved cases.  
Variants (SNVs, indels, and large deletions) were identified that fulfil the following 
criteria: in an unsolved case where an individual has undergone WGS, are high 
impact and autosomal, the genotype is consistent with autosomal recessive 
inheritance, have MAF <0.001 in the control datasets described, are in the Ensembl 
canonical transcript, are in a gene that contains no homozygous predicted protein-
truncating variants in the ExAC database, and appear to be real on examination in 
IGV. This analysis was not limited to IRD-associated genes, but included all protein-
coding genes. 
 
Results 
  11 
In a highly heterogeneous cohort of individuals with inherited retinal disease, 
high-throughput sequencing achieves a pathogenic variant detection rate of 
56% 
High-throughput sequencing was performed on a cohort of 722 individuals with IRD, 
as part of the NIHR-BioResource Rare Diseases research study. 605 of the 
individuals had WGS, 72 had WES, and an additional 45 had both. For WGS 
average coverage was 37X (SD = 2.7), with a minimum of 95% of each genome 
covered to at least 15X. For WES average target coverage was 43X (SD = 14.9), 
with 83% of target bases covered to at least 15X.  
The cohort is phenotypically heterogeneous, and the most frequent phenotypes are 
retinitis pigmentosa (n=311), retinal dystrophy (n=101), cone-rod dystrophy (n=53), 
Stargardt disease (n=45), macular dystrophy (n=37), and Usher syndrome (n=37). 
The majority of individuals are unrelated probands (714/722), and there are three 
parent-offspring pairs and one pair of siblings. The majority of the cohort had a 
negative result for a genetic test, such as single gene Sanger sequencing or targeted 
gene panel sequencing, prior to enrolment in the current study. 
To identify the pathogenic variants, rare, coding, and high-quality variants, including 
large deletions, in 224 genes that are known to be associated with IRD, were 
considered. The likely cause of IRD was identified in 404/722 individuals, 
corresponding to a pathogenic variant detection rate of 56% (table 1, table S2). A 
further 5% of individuals (36/722) have been classified as partially solved. These 
individuals either have a single likely pathogenic variant in a known gene associated 
with recessive IRD and in keeping with the individual’s phenotype, more than two 
heterozygous variants in a gene associated with recessive IRD, or a variant that only 
explains part of the phenotype (table S2). The remaining 282/722 (39%) of 
individuals remains without a complete or partial molecular diagnosis. 
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By using WES alone we were able to identify pathogenic variants in 59/117 (50%) 
individuals. Subsequently, 45 of the 58 individuals who were unsolved by WES 
underwent WGS, and we identified or confirmed pathogenic variants in a further 14 
(table 1). For three individuals the bait for the variant location was absent from the 
capture kit (Roche NimbleGen, SeqCap EZ Exome v3), for two individuals each had 
a large deletion not called by WES and, in one individual, a large indel was also not 
called by WES.  For three more individuals, the variant was called by WES but the 
quality was poor. For the remaining five individuals, although the variants were 
identified by WES, they were not the expected mode of inheritance for the family, 
therefore WGS was performed to exclude more plausible cause of disease by 
including analysis of copy number variants and exons of high GC content. 
The pathogenic variant detection rate also varies depending on the phenotype of the 
individual (table 2). For example, 168/311 (54%) of individuals with retinitis 
pigmentosa have been solved, which is similar to the overall rate; 31/37 (84%) of 
individuals with Usher syndrome have been solved but only 6/21 (29%) of individuals 
with cone dystrophy have been solved. Also, individuals who had not had any 
genetic test prior to this study had a notably higher pathogenic variant detection rate 
than the overall rate. Of 152 individuals who had no pre-screening, including 
individuals with a diagnosis of retinitis pigmentosa, cone dystrophy or congenital 
stationary night blindness, 96 were solved (63%), suggesting that our cohort is 
enriched for intractable cases. 
The pathogenic variant detection rate within our cohort also varies depending on the 
ethnicity of the individual (table 3). Likely ethnicity was estimated from the WGS data. 
Only 13/43 (30%) of individuals of African ancestry were solved, compared to 
259/467 (55%) of individuals of European ancestry and 70/123 (57%) of individuals 
of South Asian ancestry. Higher genetic diversity in African populations, combined 
with underrepresentation of non-European populations in control datasets, result in 
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an excess of rare and apparently rare variation in these individuals, rendering variant 
interpretation more challenging.24,30 There was a median of 12 rare coding variants in 
IRD-associated genes for manual review in individuals of European ancestry and 30 
in individuals of African ancestry. Interestingly, in individuals of South Asian ancestry, 
59/89 pathogenic variants (66%) were homozygous, compared to only 82/446 (18%) 
in individuals of European ancestry. This is likely due to increased rates of 
consanguinity in South Asian populations, and probably explains why they have 
comparable pathogenic variant detection rates to individuals of European ancestry in 
this study, despite also being underrepresented in control databases of allele 
frequencies. 
The genes in which pathogenic variants are most frequently found are summarised in 
table 4. ABCA4 [MIM: 601691] is implicated in 73/440 solved or partially solved 
cases (17%). In total, 796 pathogenic alleles were identified in 95 different known 
IRD-associated genes. Of these alleles, 687 (86.3%) are autosomal recessive, 72 
(9%) are autosomal dominant, 35 (4.4%) are X-linked hemizygous, and 2 (0.3%) are 
X-linked monoallelic. Some of the pathogenic alleles are homozygous, and some 
occur in more than one individual in the cohort, thus there are 537 different 
pathogenic alleles. Of these, 499 (92.9%) are exonic SNVs or indels, 30 (5.6%) are 
large deletions overlapping at least one exon, 6 (1.1%) are SNVs or indels that are 
synonymous or in regulatory regions, and 2 (0.4%) are tandem duplications 
overlapping at least one exon. 291/537 (54.2%) are previously unreported in 
publically available databases emphasizing the allelic heterogeneity of IRD, and the 
rest have been previously reported and are in the HGMD Pro database.23 
We performed confirmatory Sanger sequencing and segregation in families in a 
subset of variants. Of 177 alleles Sanger sequenced, all were confirmed. Of these, 
52 were tested in at least one additional informative family member, and segregated 
as expected. In five of the individuals whose case is unsolved , a pathogenic variant 
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was identified by a different method concurrent to this study. Four of these are 
variants in highly repetitive regions requiring specific optimised Sanger sequencing 
protocols, for example RPGR [MIM: 312610] exon ORF15, and one is a 
heteroplasmic variant in the mitochondrial genome, which was apparent 
retrospectively in the WGS data, but was not identified by the variant caller. 
 
Pathogenic structural variants are an important cause of IRD, and their 
detection is facilitated by WGS 
There are 33 SVs (31 deletions and 2 tandem duplications) that are pathogenic in 31 
individuals (table S2). Each SV was further investigated using either SNP genotyping 
array, direct Sanger sequencing of a unique PCR amplified product spanning the 
predicted breakpoints, or both techniques. Twenty-three (70%) have been confirmed 
by Sanger sequencing of the breakpoint, 6 (18%) have been confirmed by both 
Sanger sequencing the breakpoint and SNP genotyping array, 2 (6%) have been 
confirmed by genotyping only and 2 (6%) have not yet been confirmed by an 
alternative method, although visual inspection of the IGV plots predict a deletion. In 
seven SVs, confirmatory Sanger sequencing of PCR generated products over the 
breakpoint also revealed an insertion (1-51 bps) at the breakpoint of the variants 
predicted by the algorithms.  
The Manta algorithm, which identifies structural variants based on both paired read 
fragment spanning and split read evidence, predicts the correct breakpoints with 
100% accuracy in 13/26 SVs that were called by Manta and have been confirmed by 
Sanger sequencing. It predicts the correct breakpoints to within 3bp in 21/26 SVs. 
Interestingly, we have identified one identical SV in two unrelated individuals. 
G001296 and W000139 both have 15:89750128-89757489del, which overlaps exons 
7-9 of RLBP1 [MIM: 180090]. In G001296 the deletion is heterozygous and occurs in 
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conjunction with a second pathogenic variant, and in W000139 it is homozygous. It 
does not occur in any other individual in the NIHR BioResource Rare Diseases 
cohort. 
Case study one illustrates the power of WGS to detect SVs. Two likely pathogenic 
heterozygous variants were identified in EYS [MIM: 612424] in individual W000325, 
who presented with typical retinitis pigmentosa. The variants are a missense variant 
ENST00000503581.1:c.6473T>C (p.Leu2158Pro) that is predicted to be damaging 
by CADD (phred-scaled CADD score = 23.5) and has not been reported before in 
public databases, and a 55kb deletion (chr6:65602819-65658187del), confirmed by 
Sanger sequencing, which overlaps exons 15-18 (c.2260-2380_2847-6084del). If 
transcribed, this large deletion is predicted to lead to a frameshift and premature 
termination in exon 19 (p.R949Ifs*4). This individual had undergone WES analysis 
prior to WGS analysis, from which it was not possible to identify the pathogenic 
deletion (figure 1). 
Case study two is an interesting example of likely uniparental isodisomy discovered 
through analysis of SVs. Individual W000170 presented with an atypical early-onset 
form of retinal dystrophy. A homozygous in-frame combination indel in KCNV2 [MIM: 
607604] was first identified: 
ENST00000382082.3:c.222_232delGGACCAGCAGGinsGGTCACCACCACCTTGG 
(ENSP00000371514.3:p.Asp75_Gln77delinsValThrThrThrLeu). The mother of the 
individual is heterozygous for this indel, and the father is homozygous for the 
reference allele. By visual inspection of the surrounding region using the IGV 
software,27 a homozygous tandem duplication was identified (chr9:2717844-
2718030dup), flanking the indel (figure 2), which was confirmed by Sanger 
sequencing. Further investigation revealed a long run of homozygosity with 
approximate coordinates chr9:2100000-27400000. Taken together, we consider that 
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the most likely explanation for these observations is homozygosity for the KCNV2 
disease allele due to partial maternal uniparental isodisomy of chromosome 9. 
Case study three is an interesting example of overlapping compound heterozygous 
deletions. Individual W000164 presented with typical retinitis pigmentosa. Two likely 
pathogenic overlapping heterozygous deletions were identified using WGS. The first 
(chr6:64475599-64501270del) encompasses exons 38-40 of EYS, and the second 
(chr6:64491812-64513698del) encompasses exons 38-39 of EYS (figure 3). Sanger 
sequencing confirmed both deletions. This example illustrates the value of algorithms 
that use paired read fragment spanning evidence such as Manta. Only these are 
able to provide characterisation of breakpoints to a single base pair resolution. WES 
or indeed read depth analysis alone of WGS (e.g. the Canvas algorithm) would fail to 
characterise the breakpoints precisely, rendering Sanger sequencing confirmation or 
family analysis more difficult. 
 
WGS improves coverage of GC-rich regions compared to WES 
In the current study, we have observed increased power to detect variants in GC-rich 
regions. To assess the possible impact of this, we calculated the average coverage 
of exons of known IRD-associated genes, split into 50bp bins, in our WGS dataset 
and in the ExAC WES dataset. For exons of IRD-associated genes with a GC 
content of 45-65% the average coverage by read depth of sequence using WES is 
higher than for WGS. The calling of SNV exonic variants in this range is not 
significantly different for WES and WGS. Comparing WES from ExAC, we find 
significantly higher coverage in our WGS dataset in bins with GC <30% or >70% 
(figure 4). Additionally, the variability of coverage in our WGS data is much less than 
that of the ExAC dataset. This uniformity of coverage is one of the main factors that 
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make WGS particularly powerful for SV detection. Calling SVs in WES where the 
variance of read depth is so great is unreliable (figure 1A). 
Case study four illustrates the clinical relevance of this improvement in coverage. 
Individual G004991 presented with Leber's congenital amaurosis. Pathogenic 
compound heterozygous variants were identified in the first coding exon of GUCY2D 
[MIM: 600179], which is 76% GC (figure 5). The variants are: an in-frame deletion 
ENST00000254854.4:c.238_252delGCCGCCGCCCGCCTG (p.Ala80_Leu84del), 
not previously reported in publically available databases and a previously reported 
missense variant ENST00000254854.4:c.307G>A (p.Glu103Lys).31 This exon is not 
covered in the capture kit used for WES, and had WES been used rather than WGS 
to investigate this individual, neither pathogenic variant would have been identified. 
Furthermore, visual inspection of the sequencing reads using IGV demonstrates 
biallelic inheritance of the two variants, since they occur within 70 nucleotides and 
are never observed on the same 150bp read. 
 
WGS allows identification of pathogenic variants in non-coding regions 
In our cohort, three different pathogenic non-coding SNVs were identified. For 
example, in G008165, who presented with Stargardt disease, one intronic SNV was 
identified in ABCA4 in trans with a previously reported synonymous SNV, 
1:94466602C>T (ENST00000370225.3:c.6342G>A) that results in a premature 
donor splice site that truncates exon 46.32 The heterozygous intronic variant was 
1:94476951A>G (ENST00000370225.3:c.5461-10T>C), which has also been 
previously reported and causes aberrant splicing.33 This variant was found in 16 
individuals, all of whom presented with typical features of ABCA4-retinopathy, and 
thus represents a significant portion of disease alleles. In two of these individuals this 
variant is homozygous, in a further 9 individuals it occurs in conjunction with a 
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second heterozygous likely pathogenic allele, and in 5, we have identified no second 
likely pathogenic allele and the individuals remain partially solved. This variant is rare 
in both ExAC (MAF = 2.2 x 10-4, no homozygotes) and the whole NIHR BioResource 
Rare Diseases cohort (MAF = 1.8 x 10-3, no homozygotes other than the two 
described here). 
In another example, individual G001035, who presented with Usher syndrome, the 
deep intronic USH2A [MIM: 608400] variant 1:216064540T>C 
(ENST00000307340.3:c.7595-2144A>G) was identified. This is heterozygous and 
occurs in conjunction with a second heterozygous likely pathogenic allele. It has 
been previously reported, and results in the retention of a pseudoexon, which causes 
a frameshift and premature truncation of the protein.34 
Finally, in two unrelated males with a clinical diagnosis of choroideremia (G001372 
and G007713) we identified a deep intronic variant in CHM that has not been 
previously reported. Both individuals had previously undergone CHM screens, which 
were negative, and no convincing pathogenic coding variant was found in any IRD-
associated gene in either individual upon analysis of the WGS data. Given the 
unequivocal diagnosis of choroideremia in these individuals and the single genetic 
cause of choroideremia, the sequence of these cases was selected for interrogation 
of rare non-coding variants in CHM (chrX:85,116,185-85,302,566). We hypothesised 
that a deep intronic variant may act as a null variant by altering splicing as previously 
described.35  
A rare (MAF≤0.01) deep intronic hemizygous variant was identified in G001372 in the 
genomic region of CHM: chrX:85,220,593T>C (ENST00000357749.2:c.315-
1536A>G). Individual G007713 had three rare intronic variants, including the same 
chrX:85,220,593T>C variant. This variant is absent in the UK10K genome project 
dataset and the 1000 genomes dataset.30,36 The variant was confirmed in both 
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individuals by direct Sanger sequencing, and it was also confirmed in an affected 
male cousin of G007713, and in the heterozygous state in the mother of G007713. 
Splice prediction analysis using HSF28 and NNSPLICE0.929 demonstrated the likely 
introduction of a cryptic splice acceptor site by this variant (HSF consensus value: 
92.66, NNSPLICE0.9 score 0.94). The presence of a strong donor site (HSF 
consensus value: 84.71, NNSPLICE0.9 score: 0.89, sequence atgcaaggtaaactg) 
224bp downstream of the cryptic acceptor site suggested that a cryptic exon could 
arise from this variant (figure 6). 
To confirm this, we used RT-PCR amplification spanning exons 4-5 of CHM from 
G001372, G007713, and the heterozygous mother of G007713. This demonstrated a 
fragment approximately 200bp larger than expected (2 fragments in the 
heterozygous mother). Upon sequencing of the fragments, the predicted cryptic exon 
was confirmed. The variant is predicted to lead to a premature termination codon 
after 9 altered amino acid residues (p.S105Rfs*10). 
 
Monoallelic variants in genes associated with a recessive mode of inheritance  
Interpreting single heterozygous variants in recessive IRD-associated genes 
presents a challenge, as it is typically difficult to distinguish between a case in which 
a second pathogenic allele in the same gene has been missed, from a case in which 
the individual is just a carrier of the single heterozygous variant and the real cause of 
disease lies elsewhere. In our cohort there are only 16 individuals (2%) who have a 
single heterozygous likely pathogenic variant in a recessive IRD-associated gene. Of 
these, 12 are in ABCA4, and one is in each of CEP290 [MIM: 610142], CNGB1 [MIM: 
600724], GUCY2D, and CRB1 [MIM: 604210]. These individuals all have phenotypes 
that are strongly indicative of variants in the gene in question, and the identified 
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variant in each case is either a predicted protein-truncating variant or a missense 
previously reported as being pathogenic. We excluded the possibility that these 
individuals have an additional previously reported pathogenic deep intronic variant. 
The probability is high that at least some of these 16 partially solved individuals 
harbour a second pathogenic variant in the same gene, perhaps in a regulatory 
region, that remains elusive. This cohort is under continuing investigation to identify 
further variants, including variants in regulatory regions. The proportion of individuals 
who have a single likely pathogenic variant in an autosomal recessive gene in this 
study is lower than previously reported (2%).17 This may reflect a combination of 
detailed specialist phenotyping to reduce phenocopies and the comprehensive exon 
and non-coding coverage achieved using WGS.  
Identification of genes containing likely biallelic predicted protein-truncating 
variants in unsolved cases. 
We performed further investigation of 247 individuals, in whom no pathogenic 
variants were detected in the known IRD-associated genes, and whose family history 
is not inconsistent with recessive disease.. These were screened for any gene 
containing ≥2 predicted protein-truncating alleles, including SVs. This yielded a list of 
19 genes in 16 individuals (table 5 and table S3). None occurred in more than one 
individual, but three individuals have variants in two genes. Segregation has not 
been performed on the double heterozygous variants. None of these genes contain 
any homozygous predicted protein-truncating variants in the ExAC dataset, 
suggesting that they may not tolerate biallelic loss of function variation. 
 
Discussion 
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Overall, we have identified pathogenic variants for 404/722 individuals with IRD in 
the NIHR-BioResource Rare Diseases study, which is a pathogenic variant detection 
rate of 56%. Factors that influence this rate within our cohort include the phenotype 
of the individual, for example individuals with Usher syndrome are substantially more 
likely to receive a molecular diagnosis than individuals with retinitis pigmentosa. 
There are several possible reasons for this. First, it may be that a higher proportion 
of Usher syndrome genes overall have been identified than retinitis pigmentosa 
genes. Second, more specific phenotypes can suggest a smaller number of 
candidate genes; retinitis pigmentosa is far more genetically heterogeneous than 
Usher syndrome. Third, it is more difficult to distinguish pathogenic monoallelic 
variants from the many rare benign inherited monoallelic variants, than it is to 
distinguish pathogenic biallelic variation, therefore phenotypes that are 
predominantly recessive tend to have higher pathogenic variant detection rates. Also, 
it may be that individuals with some phenotypes were more likely to undergo some 
pre-screening prior to enrolment in the project, which would exclude individuals with 
variants in known genes and likely reduce the pathogenic variant detection rate.  
Our pathogenic variant detection rate of 56% with WGS is comparable to those 
previously reported in other similar studies of IRD, which ranges between 39-70%.10–
15,17 Factors that influence differences between these rates include the technology 
used and the degree of pre-screening performed on the cohort, as well as the 
phenotypes included and the ethnic distribution of the cohort as discussed. Our 
detection rate of 50% using WES in 117 individuals is perhaps lower than expected 
due to the WES depth of coverage of 43x used compared to diagnostic laboratory 
median coverage of >80x that is recommended 39. Our observation that the subset of 
our cohort who had no pre-screening had a higher pathogenic variant detection rate 
than the overall rate, suggests that our cohort is enriched for intractable cases, and 
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that the overall rate of 56% is an underestimate compared with what would be 
expected if WGS was used as the first-line test. 
We have observed that using primarily WGS instead of WES or targeted gene panels 
has improved our power to detect three categories of variants in particular: SVs, 
variants in GC-rich regions, and variants in regulatory regions. Previous studies have 
also observed that WGS is superior to WES for the detection of SVs, particularly 
small deletions (e.g. single exon deletions).6,37,38 This is due to high uniformity of 
coverage achieved with WGS, and the very high probability that the breakpoints of a 
SV will be covered by WGS reads. With WGS, therefore, precise characterisation of 
the SV to single base pair resolution is often possible, without any further 
investigation. 
Our study also supports previous reports that PCR-free sequencing protocols, such 
as WGS, capture genomic regions that are particularly high or low in GC content 
much more effectively than methods such as WES and targeted gene panels, which 
require a PCR amplification step.37,39 GC-rich regions tend to be poorly covered by 
methods that require a PCR amplification step due to their high stability and 
consequent resistance to standard denaturation protocols, and variant calling suffers 
as a consequence.40–42  
The WGS analysis identified three intronic variants that would not have been 
identified by standard WES without specific prior knowledge. The interpretation of 
these variants required the availability of sequence from a large number of internal 
controls (~13,000 alleles from the NIHR BioResource Rare Diseases consortium) 
and external WGS controls (~8,000 alleles from UK10K). Frequency data on non-
coding variants comparable to the ExAC dataset for coding variants is needed and 
will transform rare disease non-coding variant interpretation. Clinical WES platforms 
can be designed to target known pathogenic variants in regulatory regions in addition 
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to the exome footprint.43 However, they require regular redesign to capture newly 
reported non-coding pathogenic variants, and they do not give the option of 
identifying pathogenic deep intronic variants that have not been previously reported.  
Regarding limitations of WGS, highly repetitive regions generally still remain poorly 
covered in our WGS data, due to the difficulty of uniquely mapping the reads in these 
regions to the genome. This has previously been reported,17 and is also a problem 
for targeted gene panels and WES.13,14 This is an important issue for IRD, due to the 
existence of clinically important repetitive regions such as RPGR ORF15, which is 
highly repetitive, and is a mutational hotspot that constitutes one of the most 
common causes of X-linked retinitis pigmentosa.44 While in the future, increasing 
read lengths and improved read mapping algorithms are likely to result in improved 
coverage over these regions, currently they must still be sequenced separately using 
optimised PCR amplification and Sanger sequencing protocols to exclude the 
possibility of them harbouring pathogenic variants. WGS also remains costlier than 
targeted gene panels or WES, and so currently costs more per diagnosis.45 With the 
cost of WGS continuing to fall and the emergence of large-scale WGS projects such 
as the Genomics England 100,000 Genome Project,8 WGS is nevertheless an 
increasingly important tool for investigating genetic causes of rare diseases, 
including IRD, in clinical practice as well as research, and is likely to become the 
preferred first-line test in the future.47 
This project has already contributed to novel insights into the genetic architecture 
and phenotypic spectrum of IRD. We have identified a distinctive electroretinogram 
phenotype, predominantly involving the cone pathways, in two individuals with 
variants in CACNA2D4 [MIM: 608171].48 Additionally, an individual from this study 
with biallelic IFT140 [MIM: 614620] variants, along with additional cases, expanded 
the known phenotypic spectrum of IFT140-associated disease, which was originally 
reported as a severe syndromic ciliopathy, and is now known to also cause non-
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syndromic retinitis pigmentosa.19 Several other individuals in our cohort with variants 
in both RGR [MIM: 600342] and CDHR1 [MIM: 609502] led to the discovery that a 
recessive retinal disorder previously associated with a homozygous variant in RGR is 
more likely to be caused by the variant in CDHR1, which is in complete linkage 
disequilibrium with the originally reported variant. 46 
There are many possible reasons why 282/722 (39%) of our cohort remain as yet 
unsolved. Some may have pathogenic variants that have not been called by the 
variant calling software because, for example, they are in regions of poor coverage 
such as repetitive regions. Others may have pathogenic variants that were called but 
not manually reviewed because they did not pass one of our filters. Some are likely 
to have pathogenic variants in genes, associated with IRD that are not on our list of 
IRD-associated genes. For some unsolved individuals, the cause of their disease 
may be more complex than Mendelian inheritance, but may be oligogenic, or 
influenced by environmental factors. Finally, it is likely that a proportion of unsolved 
individuals have pathogenic variants in regulatory regions, rather than in coding 
exons. Regulatory variation is known to be an important cause of IRD.12,32,34,49,50 
Having used WGS for the majority of our cohort, we are well placed to investigate 
this class of variation. However, interpretation of regulatory variation remains a 
significant challenge. Experimental verification of specific variants is particularly 
difficult as many IRD-associated genes are restricted to expression in the retina, 
making functional confirmation of the effects of any candidate regulatory variation 
challenging. Our investigation of potentially pathogenic regulatory variation is 
ongoing. 
We have identified 19 genes that contain likely biallelic, predicted protein-truncating 
variants in unsolved individuals with IRD, including CROCC [MIM: 615776], IRX5 
[MIM: 606195] and NUMB [MIM: 603728] that have known roles in retinal 
development and function.51,52 These may represent strong candidates for previously 
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unreported recessive IRD-associated genes (table S3). Identification of at least two 
additional individuals with likely pathogenic variants is necessary to provide sufficient 
supportive evidence of any of these genes being associated with IRD.  
In conclusion, we present here a large cohort of individuals with IRD who have had 
WGS, and we have achieved a pathogenic variant detection rate of 56%. We have 
identified three categories of pathogenic variant that WGS substantially improves the 
detection of: SVs, variants in GC-rich regions, and variants in regulatory regions. 
Studying a cohort of this size using WGS provides new insights into phenotypes and 
the genetic architecture of IRD. In the future, WGS is likely to become the preferred 
choice of test with which to investigate the genetic causes of IRD. 
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Figures 
 
Figure 1: Case study 1, WGS increases power to detect SVs, compared to 
WES. A: One individual (W000325) with retinitis pigmentosa has a pathogenic 
heterozygous deletion within EYS (6:65602819-65658187). IGV plots showing the 
deleted region in both WGS and WES data in the individual. The deletion was 
identified by WGS due to the drop in coverage and increased distance between 
mate-paired reads. However, it was not identified from WES data. B: The individual 
also has a pathogenic missense variant ENST00000503581.1:c.6473T>C 
(p.Leu2158Pro). 
 
Figure 2: Case study 2, identification of pathogenic tandem duplication and 
likely UPD by WGS. One individual (W000170) with atypical, early-onset retinal 
dystrophy, has a homozygous pathogenic tandem duplication within KCNV2, likely 
due to partial maternal uniparental isodisomy of chromosome 9. A: IGV plot showing 
the 184bp tandem duplication of 9:2717844-2718028 in WGS data. B: The tandem 
duplication was confirmed by PCR and Sanger sequencing. The arrows represent 
the positions of the primers. C: There is a ~25Mb region of homozygosity in 
chromosome 9 in this individual, which encompasses KCNV2. Approximate 
coordinates of this region of homozygosity are 9:2100000-27400000. D: Sanger 
sequencing also confirms a homozygous combined in-frame insertion/deletion in 
KCNV2, within the tandem duplication: 
ENST00000382082.3:c.222_232delGGACCAGCAGGinsGGTCACCACCACCTTGG 
(ENSP00000371514.3:p.Asp75_Gln77delinsValThrThrThrLeu). The mother of the 
affected individual is heterozygous for this variant, but the father is homozygous for 
the reference allele (not shown). 
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Figure 3: Case study 3, identification and characterisation of compound 
heterozygous deletions in EYS by WGS. A: one individual (W000164) with retinitis 
pigmentosa has compound heterozygous deletions in EYS, shown by the green 
dashed lines. B: Sanger sequencing confirmed both deletions. Sequencing across 
the breakpoint (vertical dashed line) of deletion 2 is shown. 
 
Figure 4: Regions of IRD-associated genes that are low or high in GC content 
have significantly higher coverage in WGS data than in the ExAC WES project. 
Coverage was calculated across protein-coding regions of autosomal IRD-associated 
genes (Ensembl canonical transcript), split into 50bp bins. Coverage shown is 
relative to the average coverage of each dataset. Error bars show standard 
deviation. * =  p < 1 x 10-15. 
 
Figure 5: Case study 4, Identification of pathogenic variants by WGS in GC-rich 
regions not covered by WES. One individual (G004991) with Leber's congenital 
amaurosis has pathogenic compound heterozygous variants 
ENST00000254854.4:c.238_252delGCCGCCGCCCGCCTG (p.Ala80_Leu84del) 
and ENST00000254854.4:c.307G>A (p.Glu103Lys) in exon 1 of GUCY2D, which is 
76% GC-rich. This exon is not covered by WES in our cohort, as demonstrated by 
the WES data of a control sample shown here. It is also not well covered in ExAC. 
 
Figure 6: The deep intronic CHM variant c.315-1536A>G results in the inclusion 
of a cryptic exon. A: Sequence of the cryptic exon included by the deep intronic 
  40 
CHM variant chrX:85,220,593T>C (ENST00000357749.2:c.315-1536A>G). B: RT-
PCR showing increased size of fragment due to inclusion of the cryptic exon. 
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Tables 
 
Sequencing method Total cases Cases solved Cases partially 
solved 
Cases 
unsolved 
WGS 605 331 (55%) 31 (5%) 243 (40%) 
WES 72 59 (82%) 3 (4%) 10 (14%) 
WES and WGS 45 14 (31%) 2 (4%) 29 (64%) 
TOTAL 722 404 (56%) 36 (5%) 282 (39%) 
Table 1: Pathogenic variant detection rates by sequencing technology. WES 
alone solved 59/117 (50%) cases. Subsequently, 45 of the 58 cases which are 
unsolved by WES  also underwent WGS. Partially solved cases either have one 
likely pathogenic variant in a gene with biallelic inheritance, or more than two 
heterozygous variants in a gene with biallelic inheritance, or a variant that only 
appears to explain part of the phenotype.  
 
Phenotype Total  cases Cases solved 
Cases partially 
solved 
Cases 
unsolved 
RP 311 168 (54%) 11 (4%) 132 (42%) 
RD 101 55 (54%) 5 (5%) 41 (41%) 
CRD 53 29 (55%) 3 (6%) 21 (40%) 
Stargardt 45 27 (60%) 10 (22%) 8 (18%) 
Macular dystrophy 37 18 (49%) 1 (3%) 18 (49%) 
Usher 37 31 (84%) 2 (5%) 4 (11%) 
Other 27 10 (37%) 0 (0%) 17 (63%) 
CSNB 26 23 (88%) 0 (0%) 3 (12%) 
Cone dystrophy 21 6 (29%) 1 (5%) 14 (67%) 
Multiple 21 6 (29%) 3 (14%) 12 (57%) 
LCA 18 16 (89%) 0 (0%) 2 (11%) 
Achromatopsia 9 6 (67%) 0 (0%) 3 (33%) 
Albinism 8 6 (75%) 0 (0%) 2 (25%) 
FEVR 8 3 (38%) 0 (0%) 5 (62%) 
TOTAL 722 404 (56%) 36 (5%) 282 (39%) 
Table 2: Pathogenic variant detection rate by phenotype. RP = retinitis 
pigmentosa, RD = retinal dystrophy, CRD = cone-rod dystrophy, Other = any 
phenotype with frequency of less than eight, CSNB = congenital stationary night 
blindness, Multiple = more than one phenotype including syndromic cases, LCA = 
Leber congenital amaurosis, FEVR = Familial exudative vitreoretinopathy.  
 
 
 
 
 
 
 
  42 
Likely ethnicity Total cases Cases solved 
Cases partially 
solved 
Cases 
unsolved 
EUR 467 259 (55%) 23 (5%) 185 (40%) 
SAS 123 70 (57%) 4 (3%) 49 (40%) 
AFR 43 13 (30%) 4 (9%) 26 (60%) 
EAS 13 1 (8%) 1 (8%) 11 (85%) 
AMR 4 2 (50%) 1 (25%) 1 (25%) 
TOTAL 650 345 (53%) 33 (5%) 272 (42%) 
Table 3: Pathogenic variant detection rate by ethnicity. Likely ethnicity estimated 
from WGS data using principal component analysis. Table includes individuals who 
had WGS only. EUR = European, SAS = South Asian, AFR = African, EAS = East 
Asian, AMR = Ad Mixed American. 
 
 
 
Gene Total cases Cases solved Cases partially solved 
ABCA4 73 57 16 
USH2A 61 50 11 
EYS 16 15 1 
RP1 16 16 0 
CACNA1F 13 13 0 
RPGR 13 13 0 
CRB1 12 11 1 
CNGB1 9 8 1 
MYO7A 8 8 0 
PDE6B 8 8 0 
BBS1 7 7 0 
CERKL 7 7 0 
CNGB3 7 7 0 
PROM1 7 7 0 
RHO 7 7 0 
CDHR1 6 6 0 
CLN3 6 6 0 
PRPF31 6 6 0 
PRPH2 6 6 0 
RP2 5 5 0 
TRPM1 5 5 0 
Table 4: Number of solved and partially solved cases by gene. Only genes with 
pathogenic variants in five or more individuals are shown. 
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Individual Phenotype Sex Ethnicity Gene Variant genomic Variant HGVSc Variant HGVSp GT Consequence Description 
G001284 Multiple F SAS SCAPER 15:76998312G>A ENST00000563290.1:c.2179C>T p.Arg727Ter 0/1 stop_gained 
S-phase cyclin A-associated 
protein in the ER 
G001284 Multiple F SAS SCAPER 15:77064214CA>C ENST00000563290.1:c.1116delT p.Val373SerfsTer21 0/1 frameshift 
S-phase cyclin A-associated 
protein in the ER 
G001298 RD F SAS FUT5 19:5867071G>T ENST00000252675.5:c.666C>A p.Tyr222Ter 1/1 stop_gained 
fucosyltransferase 5 (alpha (1,3) 
fucosyltransferase) 
G001298 RD F SAS PODNL1 19:14046820C>CAGCT ENST00000339560.5:c.374_377dupAGCT p.Gln127AlafsTer119 1/1 frameshift podocan-like protein 1-like 
G001411 RP M AFR NAALADL1 11:64812774G>GC ENST00000358658.3:c.2191dupG p.Ala731GlyfsTer9 0/1 frameshift 
N-acetylated alpha-linked acidic 
dipeptidase-like 1 
G001411 RP M AFR NAALADL1 11:64822078G>A ENST00000358658.3:c.736C>T p.Arg246Ter 0/1 stop_gained 
N-acetylated alpha-linked acidic 
dipeptidase-like 1 
G005002 CRD M SAS WASF3 
13:27216381GTGTTTTCAATTTTCA
GATTGTGAACCA>G 
ENST00000335327.5:c.-10-
14_3delTTTTCAATTTTCAGATTGTGAACCATG NA 1/1 splice_acceptor 
WAS protein family, member 3 
G005019 Usher F SAS PLD4 14:105395186GC>G ENST00000392593.4:c.388delC p.Gln130ArgfsTer108 0/1 frameshift phospholipase D family, member 4 
G005019 Usher F SAS PLD4 14:105398102CTGTCCCCA>C ENST00000392593.4:c.937_944delTGTCCCCA p.Cys313GlyfsTer167 0/1 frameshift phospholipase D family, member 4 
G005203 RP F SAS FAM71A 1:212799206T>TGCAG ENST00000294829.3:c.991_994dupGGCA p.Thr332ArgfsTer88 1/1 frameshift 
family with sequence similarity 71, 
member A 
G005251 
Cone 
dystrophy M SAS POMZP3 7:76240807T>TG ENST00000310842.4:c.538dupC p.Gln180ProfsTer14 1/1 frameshift 
POM121 and ZP3 fusion 
G005492 RP F EUR IRX5 16:54967694CTAAAG>C ENST00000394636.4:c.1362_1366delTAAAG p.Lys455ProfsTer19 1/1 frameshift iroquois homeobox 5 
G005513 Stargardt M EUR ITIH2 10:7776934CT>C ENST00000358415.4:c.1838delT p.Leu613ArgfsTer5 0/1 frameshift 
inter-alpha-trypsin inhibitor heavy 
chain 2 
G005513 Stargardt M EUR ITIH2 10:7780709CAT>C ENST00000358415.4:c.2084_2085delAT p.His695ArgfsTer5 0/1 frameshift 
inter-alpha-trypsin inhibitor heavy 
chain 2 
G005514 RP M AFR SLC37A3 7:140064249G>A ENST00000326232.9:c.334C>T p.Arg112Ter 1/1 stop_gained solute carrier family 37, member 3 
G007696 CRD M SAS NUMB 14:73746066G>GC ENST00000355058.3:c.1162dupG p.Ala388GlyfsTer6 1/1 frameshift numb homolog (Drosophila) 
G007696 CRD M SAS FAM57B 16:30038139GC>G ENST00000380495.4:c.234delG p.Gln79AsnfsTer43 1/1 frameshift 
family with sequence similarity 57, 
member B 
G007723 RP M SAS FOXI2 10:129536034AC>A ENST00000388920.4:c.498delC p.Asp166GlufsTer87 1/1 frameshift forkhead box I2 
G008152 RP M EUR CROCC 1:17292217G>A ENST00000375541.5:c.4406-1G>A NA 1/1 splice_acceptor ciliary rootlet coiled-coil, rootletin 
W000146 RP F EUR CCZ1B 7:6844600C>A 
ENST00000316731.8:c.1075G>TENST0000037
5541.5:c.4406-1G>A p.Glu359Ter 1/1 stop_gained 
CCZ1 vacuolar protein trafficking 
and biogenesis associated 
homolog B (S. cerevisiae) 
W000278 Other F SAS OR2M7 1:248487484AG>A ENST00000317965.2:c.386delC p.Pro129LeufsTer2 1/1 frameshift 
olfactory receptor, family 2, 
subfamily M, member 7 
W000375 RP M SAS PRTFDC1 10:25231367T>C ENST00000320152.6:c.49-2A>G NA 1/1 splice_acceptor 
phosphoribosyl transferase domain 
containing 1 
W000375 RP M SAS UBAP1L 15:65395024T>G ENST00000559089.1:c.121-2A>C NA 1/1 splice_acceptor ubiquitin associated protein 1-like 
 
Table 5: High-impact, likely biallelic variants in 19 genes in unsolved cases. Genomic coordinates refer to genome build GRCh37. Analysis is limited 
to cases that underwent WGS in whom pathogenic variants in known genes were not detected, and whose family history is not inconsistent with recessive 
inheritance of disease. RP = retinitis pigmentosa, RD = retinal dystrophy, CRD = cone-rod dystrophy, Other = any phenotype with frequency of less than 
eight individuals, Multiple = more than one phenotype including syndromic cases. 
 
